Hepatobiliary Imaging in Liver-directed Treatments

Hepatobiliary scintigraphy (HBS) is an emerging tool in the assessment of hepatic function. This nuclear imaging technique can be used to calculate both global and regional liver function. It has proven to be the most reliable way of assessing the distribution of liver function, especially in patien...

Full description

Saved in:
Bibliographic Details
Published in:Seminars in nuclear medicine 2019-05, Vol.49 (3), p.227-236
Main Authors: van Roekel, Caren, Reinders, Margot T.M., van der Velden, Sandra, Lam, Marnix G.E.H., Braat, Manon N.G.J.A.
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c374t-d48d010de82a67f8744914ecdbade46ffd129c03eb863acb247658efe3d6d92e3
cites cdi_FETCH-LOGICAL-c374t-d48d010de82a67f8744914ecdbade46ffd129c03eb863acb247658efe3d6d92e3
container_end_page 236
container_issue 3
container_start_page 227
container_title Seminars in nuclear medicine
container_volume 49
creator van Roekel, Caren
Reinders, Margot T.M.
van der Velden, Sandra
Lam, Marnix G.E.H.
Braat, Manon N.G.J.A.
description Hepatobiliary scintigraphy (HBS) is an emerging tool in the assessment of hepatic function. This nuclear imaging technique can be used to calculate both global and regional liver function. It has proven to be the most reliable way of assessing the distribution of liver function, especially in patients with impaired liver function due to, for example, cirrhosis or after chemotherapy. There are two types of tracers: Technetium-99m with a type of iminodiacetic acid and Technetium-99m galactosyl human serum albumin. The main indication for HBS is the assessment of the future liver remnant function in patients scheduled to undergo hemihepatectomy; to predict the risk of posthepatectomy liver failure. Another upcoming indication is the use of HBS in patients undergoing radioembolization.
doi_str_mv 10.1053/j.semnuclmed.2019.01.007
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2205408973</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0001299819300145</els_id><sourcerecordid>2205408973</sourcerecordid><originalsourceid>FETCH-LOGICAL-c374t-d48d010de82a67f8744914ecdbade46ffd129c03eb863acb247658efe3d6d92e3</originalsourceid><addsrcrecordid>eNqFkMtOwzAQRS0EglL4BZQlm4TxK7GXUAFFqsSmrC3HnlSu8ih2isTfk6pFLFnNYs6dqzmEZBQKCpI_bIuEXb93bYe-YEB1AbQAqM7IjEqpclEyfk5mAEBzprW6ItcpbQGYlFpekisOWgqq9IywJe7sONShDTZ-Z2-d3YR-k4U-W4UvjLkPEd2IPltHtGOH_ZhuyEVj24S3pzknHy_P68UyX72_vi0eV7njlRhzL5QHCh4Vs2XVqEoITQU6X1uPomwaT5l2wLFWJbeuZqIqpcIGuS-9Zsjn5P54dxeHzz2m0XQhOWxb2-OwT4YxkAKUrviEqiPq4pBSxMbsYuimhwwFczBmtubPmDkYM0DNZGyK3p1a9vVh9xv8VTQBT0cAp1-_AkaTXMDe4VGN8UP4v-UHXiSCDw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2205408973</pqid></control><display><type>article</type><title>Hepatobiliary Imaging in Liver-directed Treatments</title><source>Elsevier:Jisc Collections:Elsevier Read and Publish Agreement 2022-2024:Freedom Collection (Reading list)</source><creator>van Roekel, Caren ; Reinders, Margot T.M. ; van der Velden, Sandra ; Lam, Marnix G.E.H. ; Braat, Manon N.G.J.A.</creator><creatorcontrib>van Roekel, Caren ; Reinders, Margot T.M. ; van der Velden, Sandra ; Lam, Marnix G.E.H. ; Braat, Manon N.G.J.A.</creatorcontrib><description>Hepatobiliary scintigraphy (HBS) is an emerging tool in the assessment of hepatic function. This nuclear imaging technique can be used to calculate both global and regional liver function. It has proven to be the most reliable way of assessing the distribution of liver function, especially in patients with impaired liver function due to, for example, cirrhosis or after chemotherapy. There are two types of tracers: Technetium-99m with a type of iminodiacetic acid and Technetium-99m galactosyl human serum albumin. The main indication for HBS is the assessment of the future liver remnant function in patients scheduled to undergo hemihepatectomy; to predict the risk of posthepatectomy liver failure. Another upcoming indication is the use of HBS in patients undergoing radioembolization.</description><identifier>ISSN: 0001-2998</identifier><identifier>EISSN: 1558-4623</identifier><identifier>DOI: 10.1053/j.semnuclmed.2019.01.007</identifier><identifier>PMID: 30954189</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><ispartof>Seminars in nuclear medicine, 2019-05, Vol.49 (3), p.227-236</ispartof><rights>2019 Elsevier Inc.</rights><rights>Copyright © 2019 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c374t-d48d010de82a67f8744914ecdbade46ffd129c03eb863acb247658efe3d6d92e3</citedby><cites>FETCH-LOGICAL-c374t-d48d010de82a67f8744914ecdbade46ffd129c03eb863acb247658efe3d6d92e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30954189$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van Roekel, Caren</creatorcontrib><creatorcontrib>Reinders, Margot T.M.</creatorcontrib><creatorcontrib>van der Velden, Sandra</creatorcontrib><creatorcontrib>Lam, Marnix G.E.H.</creatorcontrib><creatorcontrib>Braat, Manon N.G.J.A.</creatorcontrib><title>Hepatobiliary Imaging in Liver-directed Treatments</title><title>Seminars in nuclear medicine</title><addtitle>Semin Nucl Med</addtitle><description>Hepatobiliary scintigraphy (HBS) is an emerging tool in the assessment of hepatic function. This nuclear imaging technique can be used to calculate both global and regional liver function. It has proven to be the most reliable way of assessing the distribution of liver function, especially in patients with impaired liver function due to, for example, cirrhosis or after chemotherapy. There are two types of tracers: Technetium-99m with a type of iminodiacetic acid and Technetium-99m galactosyl human serum albumin. The main indication for HBS is the assessment of the future liver remnant function in patients scheduled to undergo hemihepatectomy; to predict the risk of posthepatectomy liver failure. Another upcoming indication is the use of HBS in patients undergoing radioembolization.</description><issn>0001-2998</issn><issn>1558-4623</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNqFkMtOwzAQRS0EglL4BZQlm4TxK7GXUAFFqsSmrC3HnlSu8ih2isTfk6pFLFnNYs6dqzmEZBQKCpI_bIuEXb93bYe-YEB1AbQAqM7IjEqpclEyfk5mAEBzprW6ItcpbQGYlFpekisOWgqq9IywJe7sONShDTZ-Z2-d3YR-k4U-W4UvjLkPEd2IPltHtGOH_ZhuyEVj24S3pzknHy_P68UyX72_vi0eV7njlRhzL5QHCh4Vs2XVqEoITQU6X1uPomwaT5l2wLFWJbeuZqIqpcIGuS-9Zsjn5P54dxeHzz2m0XQhOWxb2-OwT4YxkAKUrviEqiPq4pBSxMbsYuimhwwFczBmtubPmDkYM0DNZGyK3p1a9vVh9xv8VTQBT0cAp1-_AkaTXMDe4VGN8UP4v-UHXiSCDw</recordid><startdate>201905</startdate><enddate>201905</enddate><creator>van Roekel, Caren</creator><creator>Reinders, Margot T.M.</creator><creator>van der Velden, Sandra</creator><creator>Lam, Marnix G.E.H.</creator><creator>Braat, Manon N.G.J.A.</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201905</creationdate><title>Hepatobiliary Imaging in Liver-directed Treatments</title><author>van Roekel, Caren ; Reinders, Margot T.M. ; van der Velden, Sandra ; Lam, Marnix G.E.H. ; Braat, Manon N.G.J.A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c374t-d48d010de82a67f8744914ecdbade46ffd129c03eb863acb247658efe3d6d92e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van Roekel, Caren</creatorcontrib><creatorcontrib>Reinders, Margot T.M.</creatorcontrib><creatorcontrib>van der Velden, Sandra</creatorcontrib><creatorcontrib>Lam, Marnix G.E.H.</creatorcontrib><creatorcontrib>Braat, Manon N.G.J.A.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Seminars in nuclear medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van Roekel, Caren</au><au>Reinders, Margot T.M.</au><au>van der Velden, Sandra</au><au>Lam, Marnix G.E.H.</au><au>Braat, Manon N.G.J.A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hepatobiliary Imaging in Liver-directed Treatments</atitle><jtitle>Seminars in nuclear medicine</jtitle><addtitle>Semin Nucl Med</addtitle><date>2019-05</date><risdate>2019</risdate><volume>49</volume><issue>3</issue><spage>227</spage><epage>236</epage><pages>227-236</pages><issn>0001-2998</issn><eissn>1558-4623</eissn><abstract>Hepatobiliary scintigraphy (HBS) is an emerging tool in the assessment of hepatic function. This nuclear imaging technique can be used to calculate both global and regional liver function. It has proven to be the most reliable way of assessing the distribution of liver function, especially in patients with impaired liver function due to, for example, cirrhosis or after chemotherapy. There are two types of tracers: Technetium-99m with a type of iminodiacetic acid and Technetium-99m galactosyl human serum albumin. The main indication for HBS is the assessment of the future liver remnant function in patients scheduled to undergo hemihepatectomy; to predict the risk of posthepatectomy liver failure. Another upcoming indication is the use of HBS in patients undergoing radioembolization.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>30954189</pmid><doi>10.1053/j.semnuclmed.2019.01.007</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0001-2998
ispartof Seminars in nuclear medicine, 2019-05, Vol.49 (3), p.227-236
issn 0001-2998
1558-4623
language eng
recordid cdi_proquest_miscellaneous_2205408973
source Elsevier:Jisc Collections:Elsevier Read and Publish Agreement 2022-2024:Freedom Collection (Reading list)
title Hepatobiliary Imaging in Liver-directed Treatments
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T10%3A22%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hepatobiliary%20Imaging%20in%20Liver-directed%20Treatments&rft.jtitle=Seminars%20in%20nuclear%20medicine&rft.au=van%20Roekel,%20Caren&rft.date=2019-05&rft.volume=49&rft.issue=3&rft.spage=227&rft.epage=236&rft.pages=227-236&rft.issn=0001-2998&rft.eissn=1558-4623&rft_id=info:doi/10.1053/j.semnuclmed.2019.01.007&rft_dat=%3Cproquest_cross%3E2205408973%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c374t-d48d010de82a67f8744914ecdbade46ffd129c03eb863acb247658efe3d6d92e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2205408973&rft_id=info:pmid/30954189&rfr_iscdi=true